PAC CARDIO-2 Tomo 8
Contenido
REFERENCIAS

LUPUS ERITEMATOSO GENERALIZADO
  1. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. Am J Med 1975;58: 243-6.

  2. Sturfelt G, Eskilsson J, Nived O et al. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. Medicine 1992:71:216-23.

  3. Ordi J, Galve E, Vilardell M. Manifestaciones clínicas cardiovasculares. En: Font, Khamashta, Vilardell, eds. Lupus eritematoso sistémico. Barcelona. 1996. p. 183-191.

  4. Leung W, Lau C, Wong C, Leung C. Fatal cardiac tamponade in systemic lupus erythematosus: a hazard of anticoagulation. Am Heart J 1990;119: 422-423.

  5. Shearn MA. The heart in systemic lupus erythematosus. Am Heart J 1959;58:452-456.

  6. Badui E, García-Rubi D, Robles E et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 1985;36:431-441.

  7. Harvey AM, Shulman LE, Tumulty PA et al. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 1954;33:291-337.

  8. Doherty NE, Feldman G, Maurer G et al. Echocardiographic findings in systemic lupus erythematosus. Am J Cardiol 1990;65:1145-1148.

  9. Leung WH, Wong KL, Lau CP et al. Cardiac abnormalities in systemic lupus erythematosus. A prospective M-mode, cross-sectional and Doppler echocardiographic study. Int J Cardiol 1990;27:367-375.

  10. Tamburino C, Fiore C, Foti R y col. Endomyocardial biopsy in diagnosis and management of cardiovascular manifestations of systemic lupus erythematosus. Clin Rheumatol 1989;8:108-12.

  11. Libman E, Sacks B. A hiterto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924;33:701-709.

  12. Galve E, Candell-Riera J, Pigrau C et al. Prevalence, morphologic types and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 1988;319: 817-823.

  13. Cervera R, Font J, Paré C et al. Cardiac disease in systemic lupus erythematosus. Prospective study of 70 patients. Ann Rheum Dis 1991;51: 156-159.

  14. Asherson RA, Cervera R. Antiphospholipid antibodies and the heart. Circulation 1991;84:920-923.

  15. Khamashta MA, Cervera R, Asherson RA et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 1990;335: 1541-1544.

  16. Nardone Soscia PN, Romain PL. Anti-phospholipid antibodies: Is there a role in cardiac valvular disease and its thromboembolic complications? Cardiology 1992;80:1-6.

  17. Ziporen L, Goldberg I, Ordi J et al. Libman-Sacks endocarditis. A possible pathogenic role for antiphospholipid antibodies. J Clin Invest 1995.

  18. Boumpas DT, Austin HA, Fessler JB et al. Systemic lupus erythematosus: emerging concepts. Part I: Renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease. Ann Intern Med 1995;122:940-950.

  19. Mitchell SR, Cupps TR, Nashel DJ et al. Valvulitis in systemic lupus erythematosus. Am J Med 1989;86:510.

  20. Nihoyannopoulus P, Gomez PM, Joshi J et al. Cardiac abnormalities in systemic lupus erythematosus. Circulation 1990;82:369-375.

  21. Korbet SM, Scwartz MM, Lewis EJ. Immune complex deposition and coronary vasculitis in systemic lupus erythematosus. Report of two cases. Am J Med 1984;77:141-146.

  22. Petri M, Spence D, Bone LR et al. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients and preventive practices. Medicine (Baltimore) 1992;71:291-302.

  23. Hosenfud JD, Montanaro A, Hart MV et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 1984;77:286-292.

  24. Petri M, Pérez-Gutthan S, Spence D et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-519.

  25. Mandell BF. Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 1987;17: 126-141.

  26. Lee LA. Neonatal lupus erythematosus. J Invest Dermatol 1993;100:9-13.

  27. Deng J, Bair L, Shen-Schwarz S y col. Localization of Ro (SS-A) antigen in the cardiac conduction system. Arthritis Rheum 1987;30:1232-38.

  28. Buyon JP, Winchester RJ, Slade SG et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Arthritis Rheum 1993;36: 1263-73.

  29. Buyon JP, Waltuck J, Kleinman C et al. In utero identification and therapy of congenital heart block (CHB). Lupus 1995;4:116-21.

  30. Asherson RA, Higenbottam TW, Dinh Xuan AT et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990;17:1292-1298.

  31. Simonson JS, Schiller NB, Petri M et al. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1989;16:918-925.

  32. Wiedemann HP, Matthay RA. Pulmonary manifestations of the collagen vascular diseases. Clin Chest Med 1989;10:677-722.

  33. Greenstone MA. Delayed diagnosis of systemic lupus erythematosus associated pulmonary hypertension. Br J Med 1991;30:391-393.

  34. Barst RJ, Rubin LJ, McGoon MD et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-415.

  35. Groen H, Bootsma H, Postma DS et al. Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol 1993;30:1055-1057.

  36. Levy RD, Guerraty AJ, Yacoub MH et al. Prolonged survival after heart-lung transplantation in systemic lupus erythematosus. Chest 1993;104: 1903-1905.

  37. Khamashta MA, Cuadarado MJ, Mujic F et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-997.

SÍNDROME ANTIFOSFOLÍPIDO
  1. Hughes GRV, Harris N, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:486-489.

  2. Chartash EK, Lans DM, Paget SA y col. Aortic insufficiency and mitral regurgitation in patients with systemic lupus ery-thematosus and the antiphospholipid syndrome. Am J Med 1989;86:407-12.

  3. Leung W-H, Wong K-L, Lau C-P y col. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990;89: 411-19.

  4. Nihoyannopoulus P, Gómez PM, Joshi J y col. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990;82:369-75.

  5. Asherson RA, Hughes GRV. The expanding spectrum of Libman-Sacks endocarditis: the role of antiphospholipid antibodies. Clin Exp Rheum 1989;7:225-8.

  6. Asherson RA, Khamashta MA, Ordi-Ros J y col. The “primary” antiphospholipid syndrome: Major clinical and serological features. Medicine 1989;68:366-74.

  7. Khamashta MA, Cervera R, Asherson RA y col. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 1990;335: 1541-44.

  8. Galve E, Ordi J, Barquinero J y col. Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med 1992;116:293-8.

  9. Amigo MC, Nava A, Bañales JL y col. Valvulopatía en el síndrome antifosfolípido primario, cardiopatía reumática y otras cardiopatías. Relación con anticuerpo anticardiolipina. Rev Mex Reumatol 1992;7:32.

  10. Cervera R, Khamashta MA, Font J y col. High prevalence of significant heart valve lesions in patients with the “primary” antiphospholipid syndrome. Lupus 1991;1:43-47.

  11. García-Torres R, Amigo MC, De la Rosa A y col. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus 1996;5:56-61.

  12. Ford SE, Charrette EJP, Knight J y col. A possible role for antiphospholipid antibodies in acquired cardiac valve deformity. J Rheumatol 1990;17:1499-1503.

  13. Ziporen L, Goldberg I, Arad M y col. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 1996;5:196-205.

  14. Afek A, Manor R, Goldberg I y col. Increased endothelial cell expression of a3b1 integrin in Libman-Sacks endocarditis in the antiphospholipid syndrome (en prensa).

  15. Agirbasli MA, Hansen DE, Byrd BF. Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome. J Am Soc Echocardiogr 1997;10:877-80.

  16. Espínola-Zavaleta N, Vargas-Barrón J, Colmenares-Galvis T y col. Echocar-diographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J 1999;137:974-9.

  17. Nescher G, Ilany J, Rosenmann D y col. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997;27:27-35.

  18. Hojnik M, George J, Ziporen L y col. Heart valve involvement (Libman-Sacks endo-carditis) in the antiphospholipid syndrome. Circulation 1996;93:1579-87.

  19. Niaz A, Butany J. Antiphospholipid antibody syndrome with involvement of a bioprosthetic heart valve. Can J Cardiol 1998;14:951-4.

  20. Libman E, Sacks B. A hiterto undescribed form of valvular and mural endocarditis. Arch Int Med 1924;33:701-37.

  21. Alarcón-Segovia D, Sánchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989;16:482-8.

  22. Asherson RA, Higenbottam TW, Dinh Xuan AT y col. Pulmonary hypertension in a lupus clinic: Experience with twenty-four patients. J Rheumatol 1990;17:1292-8.

  23. Brucato A, Baudo F, Barberis M y col. Pulmonary hypertension secondary to thrombosis of the pulmonary vessels in a patient with the primary antiphospholipid syndrome. J Rheumatol 1994;21:942-4.

  24. Luchi ME, Asherson RA, Lahita RG. Primary idiopathic pulmonary hypertension compli-cated by pulmonary arterial thrombosis. Association with antiphospholipid anti-bodies. Arthritis Rheum 1992;35:700-5.

  25. Heath D, Edwards JE Jr. The pathology of hypertensive pulmonary vascular disease: A description of six grade structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;533-47.

  26. Wagenwoort CA. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest 1980;77:614-25.

  27. Sandoval J, Bauerle O, Palomar A y col. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994;89: 1733-44.

  28. Rich S, Brundage B. Pulmonary hyper-tension: a cellular basis for understanding the pathogenesis and treatment. JACC 1989;14:545-50.

  29. Sandoval J, Amigo MC, Barragán R y col. Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy. J Rheumatol 1996;23:772-5.

  30. Vianna JL, Khamashta MA, Ordi-Ros J y col. Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients. Am J Med 1994;96:3-9.

  31. Jamieson SW, Auger WR, Fedullo PF y col. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Surg 1993;106:116-27.

  32. Asherson RA, Khamashta MA, Baguley E y col. Myocardial infarction and antiphospholipid antibodies in SLE and related disorders. Q J Med 1989;73: 1103-116.

  33. Hamsten A, Norberg R, Bjorkholm M y col. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events. Lancet 1986;1: 113-116.

  34. Morton KE, Gavaghan TP, Krilis SA y col. Coronary artery bypass graft failure: an autoimmune phenomenon? Lancet 1986; 2:1353-1356.

  35. Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus 1998;7:S132-S134.

  36. Brown JH, Doherty CC, Allan DC y col. Fatal cardiac failure due to myocardial micro-thrombi in systemic lupus erythematosus. Br Med J 1989;298:525.

  37. Murphy JJ, Leach IA. Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J 1989;62:61-64.

  38. Leventhal LJ, Borofsky MA, Bergey PD y col. Antiphospholipid antibody syndrome with right atrial thrombosis mimicking an atrial myxoma. Am J Med 1989;87:111-113.

MIOPATÍAS INFLAMATORIAS
  1. Lynch PG. Cardiac involvement in chronic polymyositis. Br Heart J 1971;284:480-1.

  2. Schaumburg HH, Nielsen SL, Yurchak PM. Heart block in polymyositis. N Engl J Med 1971;284:480-1.

  3. Babka JC, Pepine CJ. Hyperkinetic vascular state in polymyositis. Chest 1973;64(2): 243-5.

  4. Reid JM, Murdoch R. Polymyositis and complete heart block. Br Heart J 1979; 41:628-9.

  5. Gottdiener JS, Sherber HS, Hawley RJ, Engel WK. Cardiac manifestations in polymyositis. Am J Cardiol 1978;41:1141-8.

  6. Kehoe RF, Bauerfeind R et al. Cardiac conduction defects in polymyositis. Ann Intern Med 1981;94:41-3.

  7. Askari AD, Huettner TL. Cardiac abnor-malities in polymyositis-dermatomyositis. Semin Arthritis Rheum 1982;12 (2):208-19.

  8. Haupt HM, Hutchins GM. The heart and cardiac conduction system in PM-DM: a clinicopathologic study of 16 autopsied patients. Am J Cardiol 1982;50:998-1006.

  9. Weiss J, Shark W, Fishbein M et al. The use of endomyocardial biopsy in a serious cardiac abnormality associated with polymyositis: a case report. J Rheumatol 1982;9: 299-302.

  10. Rechavia E, Rotenberg Z et al. Polymyositic heart disease. Chest 1985;88(2):309-11.

  11. Christenesen PD, Sorensen KE. Peni-cillamine-induced polymyositis with complete heart block. Eur Heart J 1989;10:1041-4.

  12. Buchpiguel CA, Roizenblatt S et al. Radioisotopic assesment of peripheral and cardiac muscle involvement and dysfunction in polymyositis-dermatomyositis. J Rheumatol 1991;18: 1359-63.

  13. Tami LF, Bhasin S. Polymorphism of the cardiac manifestations in dermatomyositis. Clin Cardiol 1993;16:240-64.

  14. Pardo J, Meruane J et al. Compromiso cardiaco en polimiositis-dermatomiositis asociada a sindrome de Sjögren. Rev Med Chile 1994;122:550-5.

  15. Sainte-Beuve C, Victor J, Penisson I, Tadei A. Troubles du rythme et de la conduction et polymyosite. Arch Mal Coeur 1994;87:1241-5

  16. Lie JT. Cardiac manifestations in polymyositis/dermatomyositis: How to get to the heart of the matter. J Rheumatol 1995; :809-11.

  17. Gonzalez-Lopez L, Gamez-Nava JI et al. Cardiac manifestations in DM-PM. Clin Exp Rheumatol 1996;14: 373-9.

  18. Diessner GR, Howard FM, Winkelman RK, et al. Laboratory tests in polymyositis. Arch Intern Med 1966;117:757-63.

  19. Manion WC. Myocarditis. Arch Pathol 1956; 61:329-40.

  20. Hill DL, Barrows HS. Identical skeletal and cardiac muscle involvement in a case of fatal polymyositis. Arch Neurol 1968;19:545-51.

  21. Bohan A, Peter JB, Bowman RI, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis-dermatomyositis. Medicine 1976;55:89-104.

  22. Le Gudulec D, Lhote F, Weinman P et al. New application of myocardial antimyosin scinti-graphy: diagnosis of myocardial disease in polymyositis. Ann Rheum Dis 1993;52:235-8.

  23. Lie JT. Myocarditis and endomyocardial biopsy in unexplained heart failure: a diagnosis in search of a disease. Ann Intern Med 1988;109: 525-8.

  24. Stern R, Godbold JH, Chess Q, Kagen LJ. ECG abnormalities in polymyositis. Arch Intern Med 1984;144:2185-9.

  25. Denbow CE, Lie JT, Trancredi RG, Bunch TW. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum 1979;22:1088-92.

  26. Oka M, Raasakka T. Cardiac involvement in polymyositis. Scand J Rheumatol 1978;7:203-8.

  27. Duska F, Bradna P, Pospisil M et al. Pyrophosphate scintigraphy and other noninvasive methods in the detection of cardiac involvement in some connective tissue diseases. Nucl Med 1987;16:28-32.

  28. Behan WM, Behan PO, Gairns J. Cardiac damage in polymyositis associated with antibodies to tissue ribonucleoproteins. Br Heart J 1987;57:176-80.

ARTRITIS REUMATOIDE
  1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the clasification of rheumatoid arthritis. Arthritis Rheum 1988;31: 315.24.

  2. Linos A, Worthington JW, O’Fallon WM, Kurkland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study on the incidence, prevalence and mortality. Am J Epidemiol 1980;111:87-98.

  3. Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. Oxford: Oxford University Press; 1993.

  4. Aho K, Koskenvuo M, Touminen J, Kaprio J. Ocurrence of rheumatoid arthritis in a nationwide series of twins. J rheumatol 1986;13:899-902.

  5. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978;298:869-71.

  6. Wisnieski JJ, Askari AD. Rheumatoid nodulosis: a relatively benign rheumatoid variant. Arch Intern Med 1981;141:615-9.

  7. Symmons DPM. Mortality in RA. Br J Rheumatol 1988;27(S1):44-54.

  8. Reilly PA, Cosh JA, Maddison PJ, et al. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients.Ann Rheum Dis 1990;49:363-9.

  9. Escalante A, Kaufman RL, Quismorio FP Jr, et al. Cardiac compression in rheumatoid pericarditis. Semin Arthritis Rheum 1990;20:148-63.

  10. Jurick AG, Graudal H. Pericarditis in rheumatoid arthritis. A clinical and radiological study. Rheumatol Int 1986; 6:37-42.

  11. Scott DGI, Bacon PA. Cardiac involvement in immunological diseases. Clin Immunol Allergy 1987;1:537-75.

  12. Hara KS, Ballard DJ, Ilstrup DM, et al. Rheumatoid pericarditis: clinical features and survival. Medicine 1990;69;81-91.

  13. Cosh JA, Lever JV. The aortic valve. En: Ansell BM, Simkin PA, eds. The heart and the rheumatic disease. London:Butterworths International Medical Reviews: Rheu-matology 1984;2:234-9.

  14. Salvarani C, Macchioni P, Mantrovani W, et al. Extra-articular manifestations of RA and HLA antigens in Northern Italy. J Rheum 1992;19:242-6.

  15. Mione S. Valentini G. Giunta A, et al. Cardiac involvement in RA: an echocardiographic study. Cardiology 1993;83:234-9.

  16. Morris PB, Imber MJ, Heinsimer JA, et al. Rheumatoid arthritis and coronary arteritis. Am J Cardiol 1986;57:689-95.

  17. Browning MJ, Banks RA, Tribe CR, et al. Ten year’s experience of an amiloid clinic-a clinicopathological survey. Q J Med 1985; 54:213-27.


ESCLERODERMIA
  1. Marich HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AL, LeRoy EC, McGreger AR, Diat F, Rosal EJ. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32:998-1006.

  2. Silman AJ. Scleroderma: Disease definition and criteria. En: Silman AJ, Hochberg MC, eds: Epidemiology of the rheumatic diseases. Oxford: Oxford University Press 1993:192-219.

  3. Douvas A. Pathogenesis: serologic correlates. En: Clemens PF, Furst DE, eds. Systemic sclerosis. Baltimore: Williams and Wilkins, 1996:175-202.

  4. Masi AT, Rodnan GP, Medsger TA Jr, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.

  5. Medsger T Jr. Systemic sclerosis (sclero-derma): clinical aspects. En: Koopman WJ, ed. Arthritis and Allied Conditions 1996: 1433-64.

  6. Steen VD. Renal involvement in systemic sclerosis. Clin Dermatol 1994;12:253-8.

  7. Roca RP, Wigley FM. Psychosocial aspects in systemic sclerosis. En: Clemens PJ, Furst DE, eds: Systemic sclerosis. Baltimore: Williams and Wilkins, 1996:501-11.

  8. Clemens PJ, Lachenbruch PA, Furst DE, Paulus HE, Sterz MG. Cardiac Score. A semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemis sclerosis. Arthritic Rheum 1991;34:1371-80

  9. Follansbee W. The cardiovascular mani-festations of systemic sclerosis (sclero-derma). Curr Probl Cardiol 1986;11: 242-98.

  10. Botstein GR, LeRoy EC. Primary heart disease in systemic sclerosis (scleroderma): advances in clinical and pathological features, pathogenesis and new therapeutic aproaches. Am Heart J 1981;102:913-9.

  11. McWorther JE, LeRoy EC. Pericardial disease in scleroderma (systemic sclerosis). Am J Med 1974;57:566-74.

  12. Ellis WW, Baer AN, Robertson RM, et al. Left ventricular disfunction induced by cold exposure in patients with systemic sclerosis. Am J Med 1986;80:385-92.

  13. Kahan A, Devaux J, Amor B, et al. Pharmacodynamic effect of dipyridamole in thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma. Ann Rheum Dis 1986;45:718-25.

  14. Lichtbroun AS, Sandhaus LM, Giorno LC, Kim H, Seibold JR. Myocardial mast cell in systemic sclerosis: a report of three fatal cases. Am J Med 1990;89:372-6.

  15. Smith JW, Clemens PJ, Levisman J, et al. Echocardiographic features of progressive systemic sclerosis (PSS). Correlation with hemodynamic and postmortem studies. Am J Med 1979;66:28-33.

  16. Clemens PJ, Furst DE, Cabeen W, et al. The relations of arrythmias and conduction disturbances to other manifestations of caldiopulmonary disease in progressive systemic sclerosis (PSS). Am J Med 1981; 71:38-46.

  17. Blom-Bulow B, Jonson B, Bauer K. Risk factors limiting exercise performance in progressive systemic sclerosis. Semin Arthritis Rheum 1983;13:174-81.

  18. Ridolfi RL, Bulkley BH, Hutchins GM. The cardiac conduction system in progressive systemic sclerosis. Clinical and pathological features of 35 patients. Am J Med 1976;61:361-6.

  19. Follansbee WP, Curtiss EI, Rahko PS, et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional co-rrelations and review of the literature. Am J Med 1985;183-92.

  20. Follansbee WP, Curtiss EI, Medsger TA Jr, et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984;310: 142-8.

  21. Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 1993;125:194-203.




Contenido
Copyright © 2005 Dr. Scope. Derechos Reservados.
Diseño y Programación: Educación Médica Contínua